Mohamed A Gashouta1, Christian A Merlo2, Matthew R Pipeling3, John F McDyer3, J W Awori Hayanga4, Jonathan B Orens2, Reda E Girgis4. 1. Internal Medicine Department, St Luke's Hospital, Chesterfield, Missouri. Electronic address: mgashouta@gmail.com. 2. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Richard DeVos Heart and Lung Transplant Program, Spectrum Health-Michigan State University, Grand Rapids, Michigan.
Abstract
BACKGROUND: Exhaled nitric oxide (FeNO), a marker of airway inflammation, is often elevated in lung transplant recipients (LTxRs) with acute rejection or infection. Isolated measurements in the setting of bronchiolitis obliterans syndrome have been variable. We sought to assess the utility of serial FeNO in predicting chronic allograft dysfunction or the presence of acute rejection or infection. METHODS: Eighty-six LTxRs underwent 325 serial FeNO measurements at an expiratory flow rate of 50 ml/s. The change in FeNO (ΔFeNO) between two measurements obtained during a stable state (ΔFeNO-SS) was compared with ΔFeNO, where the first measurement was taken during a stable state and the second during an unstable state (defined as a subsequent decline in FEV1 > 10% over 3 months [ΔFeNO-SU]) or an acute complication (acute rejection, lymphocytic bronchiolitis or acute infection [ΔFeNO-SAC]). The median follow-up time after the baseline FeNO was 10 (range 3 to 25) months. RESULTS: ΔFeNO-SS in 117 FeNO pairs was similar to ΔFeNO-SU in 26 pairs (2.1 ± 3 ppb vs 2.3 ± 4 ppb; p = 0.2). ΔFeNO-SAC in 17 pairs was markedly increased (27 ± 20 ppb; p < 0.001 vs ΔFeNO-SS). The area under the receiver-operating characteristic curve for ΔFeNO in detecting an acute complication was 0.93 (p < 0.001). By applying a cut-off of >10 ppb, the sensitivity and specificity was 82% and 100%, respectively, with positive and negative predictive values of 100% and 97.5%. CONCLUSIONS: Changes in FeNO may serve as a useful adjunct in the detection of acute complications after lung transplantation. In this limited analysis, ΔFeNO was not predictive of a subsequent decline in allograft function.
BACKGROUND: Exhaled nitric oxide (FeNO), a marker of airway inflammation, is often elevated in lung transplant recipients (LTxRs) with acute rejection or infection. Isolated measurements in the setting of bronchiolitis obliterans syndrome have been variable. We sought to assess the utility of serial FeNO in predicting chronic allograft dysfunction or the presence of acute rejection or infection. METHODS: Eighty-six LTxRs underwent 325 serial FeNO measurements at an expiratory flow rate of 50 ml/s. The change in FeNO (ΔFeNO) between two measurements obtained during a stable state (ΔFeNO-SS) was compared with ΔFeNO, where the first measurement was taken during a stable state and the second during an unstable state (defined as a subsequent decline in FEV1 > 10% over 3 months [ΔFeNO-SU]) or an acute complication (acute rejection, lymphocytic bronchiolitis or acute infection [ΔFeNO-SAC]). The median follow-up time after the baseline FeNO was 10 (range 3 to 25) months. RESULTS: ΔFeNO-SS in 117 FeNO pairs was similar to ΔFeNO-SU in 26 pairs (2.1 ± 3 ppb vs 2.3 ± 4 ppb; p = 0.2). ΔFeNO-SAC in 17 pairs was markedly increased (27 ± 20 ppb; p < 0.001 vs ΔFeNO-SS). The area under the receiver-operating characteristic curve for ΔFeNO in detecting an acute complication was 0.93 (p < 0.001). By applying a cut-off of >10 ppb, the sensitivity and specificity was 82% and 100%, respectively, with positive and negative predictive values of 100% and 97.5%. CONCLUSIONS: Changes in FeNO may serve as a useful adjunct in the detection of acute complications after lung transplantation. In this limited analysis, ΔFeNO was not predictive of a subsequent decline in allograft function.
Authors: Jason D Christie; Leah B Edwards; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; David O Taylor; Anna Y Kucheryavaya; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2009-10 Impact factor: 10.247
Authors: M Paraskeva; M Bailey; B J Levvey; A P Griffiths; T C Kotsimbos; T P Williams; G Snell; G Westall Journal: Am J Transplant Date: 2011-07-27 Impact factor: 8.086
Authors: Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor Journal: Am J Respir Crit Care Med Date: 2011-09-01 Impact factor: 21.405
Authors: C Neurohr; P Huppmann; S Leuschner; W von Wulffen; T Meis; H Leuchte; F Ihle; G Zimmermann; C Baezner; R Hatz; H Winter; L Frey; P Ueberfuhr; I Bittmann; J Behr Journal: Am J Transplant Date: 2010-11-18 Impact factor: 8.086
Authors: Peter J Barnes; Raed A Dweik; Arthur F Gelb; Peter G Gibson; Steven C George; Hartmut Grasemann; Ian D Pavord; Felix Ratjen; Philip E Silkoff; D Robin Taylor; Noe Zamel Journal: Chest Date: 2010-09 Impact factor: 9.410
Authors: Allan R Glanville; Christina L Aboyoun; Adrian Havryk; Marshall Plit; Steven Rainer; Monique A Malouf Journal: Am J Respir Crit Care Med Date: 2008-02-08 Impact factor: 21.405
Authors: Antonius Schneider; Lisa Tilemann; Tjard Schermer; Lena Gindner; Gunter Laux; Joachim Szecsenyi; Franz Joachim Meyer Journal: Respir Res Date: 2009-03-03
Authors: Elizabeth A Belloli; Tian Gu; Yizhuo Wang; Dharshan Vummidi; Dennis M Lyu; Michael P Combs; Aamer Chughtai; Susan Murray; Craig J Galbán; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2021-10-15 Impact factor: 30.528